We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current OTLC market cap is 14.57M. The company's latest EPS is USD -0.0198 and P/E is -2.02.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 1.74M | 0 | 0 | 70k |
| Operating Income | -4.31M | -7.59M | -9.13M | -9.72M | -6.65M |
| Net Income | -6.64M | -9.5M | -9.39M | 5.1M | -7.9M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 23.69M | 23.66M | 23.61M | 36.12M | 30.02M |
| Total Liabilities | 6.78M | 11.18M | 15.46M | 16.92M | 18.4M |
| Total Equity | 16.9M | 12.48M | 8.16M | 19.19M | 11.61M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.28M | -2.81M | -4.43M | -1.45M | -1.32M |
| Investing | 189k | N/A | N/A | N/A | N/A |
| Financing | 2.17M | 3.22M | 4.53M | 1.13M | 1.25M |
| Market Cap | 14.57M |
| Price to Earnings Ratio | -2.02 |
| Price to Sales Ratio | 200 |
| Price to Cash Ratio | 100 |
| Price to Book Ratio | 1.38 |
| Dividend Yield | - |
| Shares Outstanding | 399.18M |
| Average Volume (1 week) | 57.19k |
| Average Volume (1 Month) | 89.54k |
| 52 Week Change | 14.06% |
| 52 Week High | 0.05 |
| 52 Week Low | 0.01 |
| Spread (Intraday) | 0.01 (29.29%) |
| Company Name | Oncotelic Therapeutics Inc (QB) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.oncotelic.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
